Early identification of acute myeloid leukemia patients with persistent disease after cytarabine and an anthracycline (7+3) induction is crucial to improve outcome. In the present retrospective study we analyzed the previously described methods to predict outcome of induction. Rapid clearance of peripheral blasts and day 14 bone marrow biopsy provided additional prognostic value over existing prognostic factors.
- Complete remission
- Day 14 bone marrow
- Peripheral blast disappearance
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't